AGENTS AFFECTING GASTROINTESTINAL FUNCTION

Acid-related gastrointestinal disorders, including peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD), represent a significant clinical burden worldwide. This study evaluates the comparative pharmacological efficacy, onset of action, and safety profiles of proton pump inhibitors (omeprazole) versus H2-receptor antagonists (famotidine) in regulating gastric acid secretion. A systematic review and comparative observational analysis were conducted on clinical cohorts receiving standard therapeutic regimens over an 8-week period. Results demonstrated that omeprazole achieved superior 24-hour intragastric pH control (\(pH > 4.0\) for \(16.4 \pm 2.1\) hours) and higher mucosal healing rates (91.2%) compared to famotidine (74.5%, \(p < 0.01\)). However, famotidine exhibited a faster initial onset of symptom relief within the first 60 minutes. Both drug classes were well-tolerated, with mild headache and gastrointestinal discomfort being the most common adverse events. In conclusion, while proton pump inhibitors remain the gold standard for sustained acid suppression and mucosal healing, H2-receptor antagonists offer valuable rapid-onset relief for episodic symptoms.